United States: Induced Infringement Of Method Of Treatment Claims: Does "United We Stand, Divided We Fall" Really Apply?

Method of treatment claims have long been part of the pharmaceutical industry's patent portfolio to protect its innovative drug products. Many such method claims, however, were drafted long ago and may arguably require more than one actor to complete all of the recited steps, a problem called "divided infringement." In 2014, the U.S. Supreme Court held in Limelight Networks, Inc. v. Akamai Technologies, Inc., 134 S. Ct. 2111, that a single entity must perform all steps of the claimed method to give rise to liability for induced infringement. This created a new issue for pharmaceutical patent litigants—could method of treatment claims be avoided simply by arguing that the steps required actions by both healthcare providers and patients? Decisions such as Endo v. Amneal, 2015 BL 279190 (S.D.N.Y. Aug. 18, 2015), where ANDA filers were not held liable for inducement of method of treatment claims requiring healthcare providers to "provide" a claimed drug product and patients to "administer" it, seemed to support that view.

Perhaps recognizing this potential issue with divided infringement, which certainly spills over to other industries as well, the Supreme Court remanded the Limelight case to the Federal Circuit to reconsider the standard for direct infringement. There the Federal Circuit held en banc that one could be liable for direct infringement even if more than one actor performs all of the claimed method steps, if "the acts of one are attributable to the other such that a single entity is responsible for the infringement." Akamai Techs., Inc. v. Limelight Networks, Inc., 797 F.3d 1020, 1022 (Fed. Cir. 2015). The acts could be attributable to a single entity when that entity directs or controls the other's performance, or if the actors formed a joint enterprise. Id.

What remained was to see how this would play out in the context of ANDA litigation involving pharmaceutical method of treatment claims. Could one combine Limelight and Akamai such that an ANDA filer could be liable for inducing direct infringement by a healthcare provider who performed at least one method step and then directed or controlled the performance of the remaining method steps by another person, e.g., a patient, diagnostic laboratory, or another physician? In other words, could Limelight inducement be predicated on Akamai direct, divided infringement in the context of method of treatment claims in ANDA cases?

With respect to a challenge to induced infringement on the basis of divided infringement, Judge Andrews of the District of Delaware provided hope to patentees, speculating: "Although the issue is not presently before the Court, I am dubious as to whether Defendant's [defense based on a divided infringement theory] will be successful in light of the Federal Circuit's en banc decision in Akamai . . . ." Takeda Pharm. Co. Ltd. v. Actavis Labs. FL, Inc., No. CV 15-451-RGA, 2016 BL 179558, n.4 (D. Del. June 6, 2016) (noting, however, that the issue "is properly a question for another day").

Recently, the Federal Circuit decided this issue in Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 845 F.3d 1357 (Fed. Cir. 2017), on appeal from the Southern District of Indiana. The patent at issue was directed to methods of administering pemetrexed disodium, a chemotherapy drug, after the patients had been premedicated with two vitamins, folic acid and vitamin B12. All of the method claims at issue required patient pretreatment by "administering" or "administration of" folic acid, followed by chemotherapeutic treatment with pemetrexed disodium. Id. at 1362. The parties had agreed that physicians gave patients the vitamin B12 and pemetrexed, but that patients self-administered the folic acid in accordance with guidance from the physician, and thus no one single actor performed all claimed method steps. Id.

In the face of a clear case of divided infringement, the Lilly decision applied the "directs or controls" standard for direct infringement that had been articulated in its en banc Akamai decision: one must (1) condition participation in an activity or receipt of a benefit upon others' performance of one or more steps of the patented method, and (2) establish the manner or timing of that performance. Id. at 1365. Holding that the relevant benefit is pemetrexed treatment, the Court held that substantial evidence supported the district court's finding that physicians condition receipt of the benefit of pemetrexed treatment on the administration of folic acid by the patient. Id. at 1366. Indeed, the Federal Circuit pointed to the product labeling, noting that folic acid is a requirement for premedication, and to evidence that a physician would refuse to give pemetrexed unless the patient had undergone the folic acid pretreatment. Id. Furthermore, the Federal Circuit rejected the arguments that "conditioning" could only be shown by imposing a legal obligation to perform the folic acid step, or by "interposing that step as an unavoidable technological prerequisite to participation." Id. at 1366-1367 (citations and quotations omitted). The Federal Circuit also rejected arguments that physicians needed to verify patients' compliance or to threaten the denial of potentially life-saving treatment. Id.

As for the second prong of the "directs or controls" test, the Federal Circuit again turned to the product labeling and expert testimony to support the district court's finding that the physician established the manner or timing—both dosage and time frame—of the folic acid pretreatment. Id. at 1367. The court was careful to point out, however, that its holding "does not assume that patient action is attributable to a prescribing physician solely because they have a physician-patient relationship." Id.

The foregoing analysis was sufficient to establish direct infringement under the Akamai standard, but what remained was the question of inducement by the ANDA filer. There, the Federal Circuit once again examined the proposed ANDA product's labeling and found "repeated instructions and warnings regarding the importance of and reasons for folic acid treatment" that are directed at physicians and that encourage or recommend infringement. Id. at 1369. As such, the Court held that while both physicians and patients were the direct infringers, the ANDA filer was liable for inducing infringement by the physicians. Even though some physicians might not adhere to the labeling's instructions and warnings, the proposed product labeling would inevitably lead at least some physicians to infringe the claimed methods, which suffices for establishing the requisite intent for inducement. Id. The Court also gave no weight to the fact that physicians may take steps beyond the instructions in the product labeling, finding their "decision to give patients even more specific guidance
is irrelevant to the question of inducement." Id.

The Federal Circuit affirmed the holding of induced infringement in the Lilly case, which bodes well for enforcement of method claims that fall within the scope of the test laid out in Akamai. Of course, it may be prudent to now draft method claims that might avoid the level of additional proof needed to survive the Akamai test for divided infringement, particularly for drugs unlike pemetrexed that do not so steadfastly require the action of two entities. The Lilly case also shows the importance, when possible, of drafting method claims grounded in the text of the product labeling to more easily survive the inducement inquiry. It remains to be seen how courts will address charges of pharmaceutical method claim inducement in the context of other situations involving divided infringement, or perhaps if reliance on contributory infringement theories may increase for post-Akamai infringement of method claims.

Previously published in BNA Pharmaceutical Law and Industry Report

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
2 Nov 2017, Webinar, Washington, DC, United States

Join us for a two-part webinar series exploring recent developments in machine learning and other technologies that have greatly advanced artificial intelligence (AI) since its origins more than 50 years ago.

9 Nov 2017, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan attorneys Adriana Burgy, Chris Johns, and Kai Rajan will discuss the Examiner Count System and provide strategies for interacting with examiners.

15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.